• By Kevin E. Noonan

    Acorda TherapeuticsOne of the statistics gleaned from Director Michelle Lee's recent blog on the post-issuance review provisions of the America Invents Act is that only 42% of inter partes review petitions have been granted over the past three years.  There is no statistic in the Director's link to a more detailed description of the data regarding the correlation between petitions being denied and the patentee exercising its right to challenge the petition by filing a Preliminary Response (see "Patent Trial and Appeal Board Statistics," July 31, 2015).  But logic suggests that the Board might be less likely to grant a petition if the patentee gave them reasons not to do so.

    This is what happened in two petitions for inter partes review filed by the Coalition for Affordable Drugs (ADROCA) against two patents owned by Acorda Therapeutics.  The Patent Trial and Appeal Board (PTAB) issued a pair of decisions today denying these petitions, using almost identical language and based on parallel reasoning.

    The patents were directed to a multiple sclerosis drug (4-aminopyridine) and methods for treating MS by administering this drug.  In one petition, ADROCA challenged claims 1-8 of U.S. Patent No. 8,663,685; claim 1 is representative:

    1.  A method of improving walking in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein the sustained release composition further comprises one or more pharmaceutically acceptable excipients.

    In the other, claims 1-3, 5-8 and 10-41 of U.S. Patent No. 8,007,826 were the subject of the ADROCA petition; claim 1 and 6 are representative:

    1.  A method for maintaining a therapeutically effective concentration of 4-aminopyridine in order to improve walking in a human with multiple sclerosis in need thereof, said method comprising: orally administering to the human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a day; and thereafter, maintaining administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, whereby an in vivo 4-aminopyridine CmaxSS:CminSS ratio of 1.0 to 3.5 and a CavSS of 15 ng/ml to 35 ng/ml are obtained in the human.

    6.  A dosing regimen method for providing a 4-aminopyridine at a therapeutically effective concentration in order to improve walking in a human with multiple sclerosis in need thereof, said method comprising: initiating administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a day without a prior period of 4-aminopyridine titration, and then, maintaining administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily; without a subsequent period of 4-aminopyridine titration, whereby an in vivo 4-aminopyridine CmaxSS:CminSS ratio of 1.0 to 3.5 and a CavSS of 15 ng/ml to 35 ng/ml are maintained in the human.

    In the petition regarding the claims of the '685 patent, petitioner asserted three grounds of invalidity, all sounding in obviousness.  The asserted references were a poster by Goodman, entitled "Placebo-Controlled Double-Blinded Dose Ranging Study of Fampridine-SR in Multiple Sclerosis" which was used alone or in combination with a poster by Hayes entitled "Open-Label, Multiple-Dose Study to Determine the Pharmacokinetics and Safety of Fampridine-SR (Sustained-Release 4- Aminopyridine) in Patients with Chronic Spinal Cord Injury."  These same references were asserted against the claims of the '826 patent, in support of two grounds of asserted obviousness in view of either the Goodman or the Hayes posters.

    The Board denied the petitions to initiate based on their determination that petitioner had not established that either poster was prior art.  As an initial matter, the Board stated that the presence of both poster references on Information Disclosure Statements (IDSs) filed by the inventors was not an admission that the references were prior art, citing citing 37 C.F.R. § 1.97(h) and Abbott Labs. v. Baxter Pharm. Prods., Inc., 334 F.3d 1274, 1279 (Fed. Cir. 2003).  The Board then set out the relevant considerations for whether a poster was a "printed publication" under 35 U.S.C. §102(b), citing In re Klopfenstein, 380 F.3d 1345, 1349 n.4 (Fed. Cir. 2004).  The evidence established that the poster was "a temporarily displayed reference that was neither distributed nor indexed" and under these circumstances the standard under Klopfenstein for showing a reference to be §102(b) prior art required consideration of the following:

    [1] the length of time the display was exhibited, [2] the expertise of the target audience, [3] the existence (or lack thereof) of reasonable expectations that the material displayed would not be copied, and [4] the simplicity or ease with which the material displayed could have been copied.

    Here, the Board found that there was insufficient evidence regarding the first prong or second prongs of the test.  The Board also commented that the posters comprised "relatively dense material in a small space," and that the "more complex a display, the more difficult it will be for members of the public to effectively capture its information," citing Klopfenstein.  On this basis the Board found that the petitioner presented insufficient evidence that there could be "any reasonable expectation that one could have copied the poster material, or evidence regarding the ease with which the poster material could have been copied."

    These determinations applied to both the Goodman and the Hayes posters and in the petitions for inter partes review of both the '685 and '826 patents, and accordingly the Board denied the petitions to institute inter partes review against either patent.

    Petitions like the ones filed against the Acorda patent have raised concerns regarding potential abuses to the inter partes review process.  However, outcomes like these, and the statistics contained in the Director's blog, suggest that any such problems may be less compelling than has been feared, particularly as more savvy observers realize that there can be a great difference between filing an inter partes review petition and having a trial instituted by the Board.

  •         By Sherri Oslick

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Reckitt Benckiser LLC v. Dr. Reddys Laboratories, Inc. et al.
    1:15-cv-04524; filed June 26, 2015 in the District Court of New Jersey

    • Plaintiff:  Reckitt Benckiser LLC
    • Defendants:  Reckitt Benckiser LLC; Dr. Reddys Laboratories, Ltd.

    Infringement of U.S. Patent Nos. 6,372,252 ("Guaifenesin Sustained Release Formulation and Tablets," issued April 16, 2002), 6,955,821 ("Sustained Release Formulations of Guaifenesin and Additional Drug Ingredients," issued October 18, 2005), and 7,838,032 ("Sustained Release of Guaifenesin" issued November 23, 2010) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of plaintiff's Mucinex® D (guaifenesin/pseudoephedrine hydrochloride, respectively, used to treat chest congestion).  View the complaint here.

    Jazz Pharmaceuticals, Inc. v. Watson Laboratories, Inc.
    2:15-cv-04532; filed June 26, 2015 in the District Court of New Jersey

    Infringement of U.S. Patent Nos. 8,859,619 ("Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy," issued October 14, 2014) and 8,952,062 (same title, issued February 10, 2015) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Jazz's Xyrem® (sodium oxybate, used to treat narcolepsy).  View the complaint here.

    Immunomedics, Inc. v. Board of Directors of Roger Williams Medical Center et al.
    2:15-cv-04526; filed June 26, 2015 in the District Court of New Jersey

    • Plaintiff:  Immunomedics, Inc.
    • Defendants:  Board of Directors of Roger Williams Medical Center; M.D., PH.D. Richard P. Junghans; M.D. Steven C Katz; Office of the Board of Advisors of Tufts University School of Medicine; ABC Entities 1-10; John Does 1-10

    Infringement of U.S. Patent Nos. 5,874,540 ("CDR-grafted Type III Anti-CEA Humanized Mouse Monoclonal Antibodies," issued February 23, 1999), 6,676,924 (same title, issued January 13, 2004), and 6,926,893 ("Multi-stage Cascade Boosting Vaccine," issued August 9, 2005) based on defendants' use, development and distribution of, and publication of information about antibodies or uses of antibodies allegedly covered by the '540 patent, and numerous claims sounding in tort.  View the complaint here.

  • Standard Essential Patents Unenforceable on Theory of Indirect Infringement

    By Joseph Herndon

    JVC KenwoodA recent decision by the Federal Circuit in JVC Kenwood Corp. v. Nero, Inc., decided August 17, 2015, involves nuanced details of standard-essential patents, but arrived at a common sense result:  either the patents at issue are standard-essential and thus licensed by defendant, or plaintiff cannot solely rely on the licensed technology standards to show infringement.

    Here, JVC Kenwood Corporation ("JVC") sued Nero, Inc. and Arcsoft, Inc. for contributory and induced infringement ("indirect infringement") of certain JVC patents directed to various uses of DVD and Blu-ray optical discs.  The charge of indirect infringement is based on Nero's sale of software to end users of DVD and Blu-ray discs, who allegedly directly infringe the JVC patents.

    Patents at Issue and Infringement Allegations

    There are six JVC Patents are at issue, directed to aspects of optical discs and specific structures, methods, or systems used with optical discs such as "jump reproduction" — e.g., fast-forwarding, fast-rewinding, etc., methods of recording moving picture data on a recording medium (i.e., burning data to DVDs and Blu-Ray discs), and methods of controlling whether certain kinds of content, such as a "R" rated movie on a DVD, should be played according to preconditions (i.e., implementation of parental controls) (see, e.g., U.S. Patent No. 6,522,692).

    The record describes two licensing pools for optical disc technology including the DVD Patent Licensing Group (also called DVD6C), and One Blue LLC for Blu-ray technology.  JVC is a member of both groups, and the Patents in suit are included in both pools, and thus, are considered standard-essential patents for this technology.

    For the DVD6C pool, the DVD6C license for DVD Patents "extends only to the structure, features and functions of a DVD Product used to practice those DVD Standard Specifications or +R/+RW Standard Specifications applicable to that DVD Product and for which the DVD Patents are Essential."  The DVD Standard Specifications are a series of documents setting forth the technical qualifications for standards-compliant products.  They are published by the DVD Forum, an international association tasked with defining the DVD Specifications.

    The One Blue patent licensing arrangement is similar.  One-Blue licenses can be obtained for specific categories of Blu-ray products, and "applies only to the extent the structure, features and functions of a BD Registered Product are used to practice" the applicable standards.

    Some of JVC's infringement contentions include that when end-users use Nero software with blank optical discs to record moving picture data, they directly infringe by practicing a specified "method of recording moving picture data on a recording medium," of one of the JVC patents.  JVC also alleged that "when the end-user then uses Nero software to reproduce (playback) the moving picture data and to fast forward (or fast reverse) through the content, the end-user directly infringes" claims of the JVC patents.  Still further, JVC alleged that when an end-user uses Nero software to perform the parental/regional control functions as recited in the claims, the end-user directly infringes claims of the JVC patents.

    For all six standard-essential JVC Patents, JVC alleged that since Nero's software customers are direct infringers, Nero is liable for induced or contributory infringement as provider of the software.

    JVC attempted to prove indirect infringement by showing that Nero is a licensed member of the DVD Format/Logo Licensing Corporation ("DVD FLLC"), the licensing agent for the DVD Forum, which is responsible for licensing the Format Books setting forth the DVD standards specifications and the DVD logo.  JVC stated that Nero is bound by the terms of the DVD FLLC license agreement, which requires all products manufactured or sold by the licensee to comply with the standards set forth in the Format Books.  JVC's theory of infringement is based on a standards-compliance theory of infringement, in that, since Nero's software necessarily complies with the standards specifications, use of Nero's software by end users for the purposes described in any of the Patents (which are standards-compliant), directly infringes the relevant Patent.

    District Court Result

    The District Court held that direct infringement of the patented systems, methods, and apparatuses, as alleged by JVC, is negated by the "extensive licensing program, both as part of the DVD6C and One Blue patent pools as well as through JVC's individual licensing program."  The District Court generally observed that licensees cannot be infringers.

    The District Court held that JVC is "barred from asserting claims of direct infringement against end users for use of Nero software with DVD and Blu-ray optical discs made or sold by a party whose products have been expressly released from claims of infringement by JVC with regard to the Patents."  The District Court also held that, absent direct infringement, Nero cannot be liable for indirect infringement.

    The District Court found that because Nero has shown an extensive licensing program, both as part of the DVD6C and One Blue patent pools as well as through JVC's individual licensing program, there cannot be infringement without specific allegations and evidence showing use of unlicensed optical discs.

    Federal Circuit Result

    JVC appealed and argued that licensees to the DVD6C pool only receive a license to those patents related to particular products, selected by the licensee, which "practice the DVD Standard Specifications" applicable to the licensee's products, citing the DVD6C License Agreement.  Thus, JVC tried to argue that Nero's license, as a member of DVD FLLC, varied from the standards-essential patent license.

    The Federal Circuit shot down JVC's arguments, and noted that, based on the proffered evidence of infringement, summary judgment of non-infringement was properly granted.  JVC cited no "specific allegations and evidence" of any unlicensed discs.

    The Federal Circuit thus affirmed the District Court's ruling, and further stated that on JVC's premise that these Patents are essential and are directly infringed by users of Nero software, it was JVC's burden to proffer at least plausible evidence in support of its position that unlicensed optical discs were in use.  JVC offered no evidence of specific unlicensed discs.

    The Federal Circuit noted that JVC cannot have it both ways — either the Patent is essential and licensed or JVC cannot solely rely on compliance with the standards to show infringement as it has chosen to do.

    While JVC may have slipped up by overlooking evidentiary procedures, or possibly was unable to prove that any unlicensed discs exist, the result here seems to come out as common sense (i.e., licensed patents cannot be infringed).  This decision is further important to provide support for the notion that such licensed patents also cannot be indirectly infringed.  While the result is not so broad, it does help support companies who have obtained licenses from later attacks of indirect infringement via use by end users.  Downstream assertion of standard-essential patents, or two bites at the apple for patent holders (a first against companies as licensees and a second against the companies as indirect infringers) is not likely to be allowed by the Federal Circuit.

    Patent Exhaustion

    An alternative holding was advanced by the District Court, however, regarding patent exhaustion.  The District Court applied Quanta and stated that "here, [JVC] has suggested no reasonable use for the [licensed DVD and Blu-ray optical discs] other than . . . practice[ing] the [JVC] Patents."

    The Federal Circuit declined to opine directly on this issue for a few reasons.  Notably, the Federal Circuit found that the District Court clearly and effectively determined that infringement had not been shown on JVC's theory and argument of the case, and thus, any further holding of patent exhaustion would have been redundant for purposes of assertion of the patents.  In addition, the Federal Circuit found that the "sketchy record, contradictory arguments, and undeveloped facts before us" did not enable them to expand the theory of patent exhaustion to reach this case.  Thus, with facts material to the issue of patent exhaustion being insufficiently developed to warrant summary judgment on that alternative ground, the District Court's ruling with respect to patent exhaustion was vacated.

    It was further noted that in arguing that the District Court improperly applied the criteria of patent exhaustion, JVC also negated its own theory of infringement (e.g., if the Patents represent a "substantial embodiment" of the optical discs as sold — as JVC argued in support of infringement — then the Patents are exhausted on sale of the discs).  This contradiction, and lack of details in evidence led the Federal Circuit to punt on the issue of patent exhaustion.

    JVC Kenwood Corp. v. Nero, Inc. (Fed. Cir. 2015)
    Panel: Circuit Judges newman, Dyk, and Reyna
    Opinion by Circuit Judge Newman

  • CalendarAugust 24, 2015 – Roadshow on Patent Quality and AIA Trials (American Intellectual Property Law Association and U.S. Patent and Trademark Office) – Santa Clara, CA

    August 26, 2015 – Roadshow on Patent Quality and AIA Trials (American Intellectual Property Law Association and U.S. Patent and Trademark Office) – Dallas, TX

    August 27, 2015 – "Meet the New Boss. Same as the Old Boss? Not Even Close under New Mayo/Alice Regime for § 101" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    August 27, 2015 – "Biosimilars: Regulation, Litigation and New Developments Patent Practitioners and Regulatory Attorneys Should Know" (American Intellectual Property Law Association) – 12:30 – 2:00 pm (Eastern)

    August 27, 2015 – "PTAB Proposed Rule Changes: What's In and What's Out?" (Foley & Lardner) – 12:00 to 1:00 pm (Eastern)

    August 28, 2015 – Roadshow on Patent Quality and AIA Trials (American Intellectual Property Law Association and U.S. Patent and Trademark Office) – Alexandria, VA

    September 1, 2015 – "IP Agreements: Structuring Indemnification and Limitation of Liability Provisions to Allocate Infringement Risk" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 2, 2015 – "Amgen v. Sandoz: What Now?" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    September 2, 2015 – "Patent Reform in the US Congress: An Overview of Current Legislation" (American Intellectual Property Law Association) – 12:00 – 1:00 pm (Eastern)

    September 10, 2015 – Biotech Patent Law Road Show (American Intellectual Property Law Association) – Boston, MA

    September 10-11, 2015 - "Advanced Patent Prosecution Seminar 2015: Claim Drafting & Amendment Writing" (Practising Law Institute) – Chicago, IL

    September 15-17, 2015 – World IP Forum (Intellectual Professionals LLP) – Bangkok, Thailand

    September 17, 2015 – "Professional Negligence: Real-Life Case Studies in IP Malpractice & How to Avoid Them" (American Intellectual Property Law Association) – 12:30 – 2:00 pm (Eastern)

    September 18, 2015 – IP & Diagnostics Symposium (Biotechnology Industry Organization) – Alexandria, VA

    September 18, 2015 – Developments in Pharmaceutical and Biotech Patent Law 2015 (Practising Law Institute) – San Francisco, CA

    September 22, 2015 – "The Evolving World of Biosimilars Litigation" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    September 24, 2015 – "Trade Secrets and Cybersecurity: Protecting Intellectual Property, Mitigating Loss and Navigating Legal Responses" (Strafford) – 1:00 to 2:30 pm (EDT)

    September 24-25, 2015 - Advanced Patent Law Seminar (Chisum Patent Academy) – Washington, DC

    September 24-25, 2015 – Seminar on European Patent Law (Grünecker) – Munich, Germany

    September 27-29, 2015 – 43rd Annual Meeting (Intellectual Property Owners Association) – Chicago, IL

    October 2, 2015 – Developments in Pharmaceutical and Biotech Patent Law 2015 (Practising Law Institute) – New York, NY

    ***Patent Docs is a media partner of this conference or CLE

  • Biotechnology Industry Organization (BIO)The Biotechnology Industry Organization (BIO) will be holding its third annual IP & Diagnostics Symposium from 8:15 am to 2:30 pm on September 18, 2015 at the Hilton Alexandria Old Town Hotel in Alexandria, VA.  The Symposium will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors.  The program will review IP issues for diagnostics and companion diagnostics, and explore new collaborations and regulatory developments.  In hosting the event, BIO aims to inform industry and government alike on how to move the science forward in the current climate.  The Symposium will offer the following presentations and sessions:

    • Session 1 — Strategies for Prevailing on Subject Matter Eligibility Before the PTO and in Litigation — Patent Docs author Donald Zuhn of McDonnell Boehnen Hulbert & Berghoff LLP will moderate a panel consisting of Gloria Fuentes, Legal Director, Patents, Merck; Eric Citron of Goldstein & Russell, P.C.; and Patent Docs author Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP (session sponsored by McDonnell Boehnen Hulbert & Berghoff LLP).

    • Session 2 — The Next Phase – How USPTO and PTAB are Identifying Patent Eligible Subject Matter — Jennifer L. Fox of Brinks Hofer Gilson & Lione will moderate a panel to be announced.

    • Session 3 — Diagnostic Tests-What’s Left to Patent? — Warren Woessner of Schwegman, Lundberg & Woessner, P.A. will moderate a panel consisting of Benjamin Jackson, Vice President Legal Affairs, Myriad Genetics; and Leslie Fischer, Senior Patent Attorney, Novartis Pharmaceuticals Corp.

    • Session 4 (Working Luncheon) — Potential Impacts of Regulatory Changes — Krista Carver of Covington & Burling LLP will moderate a panel consisting of Ellen Flannery of Covington & Burling LLP; E. David Litwack, Policy Advisor, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health; and Allen Nunnally, Associate General Counsel, IP & Corporate, Foundation Medicine, Inc.

    An agenda for the Symposium, including a list of speakers, moderators, and panelists can be obtained here.  Registration information can be found here.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Amgen v. Sandoz: What Now?" on September 2, 2015 from 2:00 to 3:00 pm (ET).  Krista Carver of Covington & Burling; Kevin Nelson of Duane Morris; and Elizabeth Weiswasser of Weil, Gotshal & Manges LLP will discuss:

    • Branded company strategy now that an innovator may have only six months notice before a biosimilar launch; the implications of having no information about the biosimilar maker’s patent strategy or manufacturing process; the new importance of competitive intelligence;
    • Biosimilar launch strategy, including the pros & cons of the BPCIA pathway – will any biosimilar aspirants still choose to go the BPCIA route?; the importance of due diligence and assessing at-risk launches;
    • New litigation dynamics outside the BPCIA, including crucial preliminary injunction battles, discovery, licensing, damages and willfulness; and
    • The next front and the end game: en banc at the Federal Circuit? How will this all end up?

    The registration fee for the webinar is $130 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Foley & LardnerFoley & Lardner will be offering a web conference entitled "PTAB Proposed Rule Changes: What's In and What's Out?" on August 27, 2015 from 12:00 to 1:00 pm (Eastern).  Stephen Maebius and Paul Hunter of Foley & Lardner LLP will review the changes to post-grant proceedings proposed by the U.S. Patent and Trademark Office on August 19, 2015 and discuss the potential impact on PTAB proceedings and legislation currently being debated in Congress.

    While there is no cost to participate in the program, advance registration is required.  Those interested in attending the webinar can register here.

  • AIPLA #1The American Intellectual Property Law Association (AIPLA) will be offering a webinar on "Patent Reform in the US Congress: An Overview of Current Legislation" on September 2, 2015 from 12:00 – 1:00 pm (Eastern).  Sharon Israel of Mayer Brown, LLP will moderate a panel consisting of AIPLA Executive Director Lisa Jorgenson, Barbara Fiacco of Foley Hoag, LLP, and Kevin Rhodes of 3M Innovative Properties Co.  The panel will examine pending legislation in the House and the Senate and how each bill proposes to address a number of significant issues, including pleadings requirements, discovery limits, fee-shifting and recovery, AIA Trial proceedings, customer stays, transparency in patent ownership, and bad faith demand letters.

    The registration fee for the program is $35 (unlimited attendees per site; no CLE available).  Those interested in registering for the program, can do so here.

  • Strafford #1Strafford will be offering a webinar/teleconference entitled "IP Agreements: Structuring Indemnification and Limitation of Liability Provisions to Allocate Infringement Risk" on September 1, 2015 from 1:00 to 2:30 pm (EDT).  Kenneth A. Sprang of Washington International Business Counsel, Daniel Winston of Choate Hall & Stewart, and Jeremy Younkin of Foley Hoag will prepare counsel to IP owners, licensees and licensors to protect their interests by allocating infringement risks during negotiations of indemnification and limitation of liability provisions in an IP agreement, and offer best practices for negotiating and structuring these provisions to allocate risk.  The webinar will review the following questions:

    • What IP-specific issues should be considered when structuring indemnification and limitation of liability provisions in IP agreements?
    • What are the most commonly disputed issues when negotiating indemnification and what are some effective strategies for resolving them?
    • What approaches should counsel use to protect a client's interests when negotiating an indemnification provision?

    The registration fee for the webinar is $297 ($362 for registration and CLE processing).  Those interested in registering for the webinar, can do so here.

  • By Kevin E. Noonan

    In the 1977 Yale Law School Holiday Pageant there was a skit about the Supreme Court, with a song sung to the tune of Cole Porter's "Another Opening, Another Show" from the musical Kiss Me Kate:

    Another opening, another term
    A chance to show that no precedent's firm
    Another opening of another term

    That parody irresistibly comes to mind with many of the Supreme Court's patent decisions (no matter how hard the Court appears to want to create the impression of consistency, Mayo and Diehr are irreconcilable) and no more so when considering the Court's end-of-term decision in Kimble v. Marvel Enterprises where the Court let stand its fifty-year ban on royalties post patent expiry (Brulotte v. Thys Co., 1964).

    Marvel EnterprisesThe facts do not provide any equities to the licensee, Marvel:  the case arose regarding U.S. Patent No. 5,072,856 to Kimble for a toy that simulated the web-shooting devices used by the fictional Spiderman.  As any child or pop culture fan knows, Marvel is the purveyor of all things Spiderman, owning the rights to the character, comic books, movies, and ancillary merchandise.  Kimble attempted to license his invention to Marvel, but they chose to copy the invention, bringing their own version of the toy to market.  The parties settled Kimble's resulting patent infringement lawsuit on terms wherein Marvel purchased the patent for a lump sum (~$500,000) plus a 3% royalty; the settlement contained no limit on this royalty obligation with regard to patent expiry.  According to the opinion, the parties were purportedly unaware of the Brulotte rule that precluded Kimble from receiving royalties after the '856 patent expired, but (once purportedly apprised of the existence of the rule) Marvel brought a declaratory judgment action against paying post-expiry royalties in which it prevailed.

    The Court affirmed Marvel's victory in an opinion by Justice Kagan, joined by Justices Scalia, Kennedy, Ginsberg, Breyer and Sotomayor; Justice Alito dissented, in an opinion joined by the Chief Justice and Justice Thomas.  While the opinion acknowledged that the Brullote rule had been the subject of judicial and scholarly criticism (citing Scheiber v. Dolby Labs., Inc., 293 F. 3d 1014, 1017–1018 (CA7 2002) (Posner, J.) and Ayres & Klemperer, Limiting Patentees' Market Power Without Reducing Innovation Incentives: The Perverse Benefits of Uncertainty and Non-Injunctive Remedies, 97 Mich. L. Rev. 985, 1027 (1999)), the majority refused to overrule it.  The reason is stare decisis seasoned with the Court's penchant for finding Congressional intent for "balance" in patent law, saying that "[i]n crafting the patent laws, Congress struck a balance between fostering innovation and ensuring public access to discoveries."  In a sentence that will resonate (badly) with patent attorneys in the throes of the consequences of the Court's recent foray into subject matter eligibility, the opinion justifies letting the Brullote rule stand saying "[t]his Court has carefully guarded that cut-off date, just as it has the patent laws' subject-matter limits" based on the public interest.  This is reflected in other examples of its precedent consistent with Brulotte, including situations where it has prevented, inter alia, parties from agreeing not to challenge a patent (citing Scott Paper Co. v. Marcalus Mfg. Co., 326 U. S. 249 (1945); Edward Katzinger Co. v. Chicago Metallic Mfg. Co., 329 U. S. 394, 400–401 (1947) and Lear, Inc. v. Adkins, 395 U. S. 653, 668–675 (1969)).

    The majority found the statutory basis for the Brulotte rule in the patent term (Sec. 154) which limits the term within which the patentee can exercise the right to exclude; thereafter the patent quid pro quo demands the invention to be freely available to the public.  The Court recognizes that "[t]he Brulotte rule, like others making contract provisions unenforceable, prevents some parties from entering into deals they desire" and that royalty plans like the one in Brulotte (and here) can have advantages including "draw[ing] out payments over time and t[ying] those payments, in each month or year covered, to a product's commercial success."  The majority also recognized the traditional justification, that "[a] more extended payment period, coupled (as it presumably would be) with a lower rate, may bring the price the patent holder seeks within the range of a cash-strapped licensee," the opinion analogizing the situation with purchasing a consumer product on an installment plan.  Alternatively, the opinion recognizes that "such an extended term may better allocate the risks and rewards associated with commercializing inventions — most notably, when years of development work stand between licensing a patent and bringing a product to market."

    Nevertheless, the Court majority believes the principle of limiting the exclusive right to the statutory term is sufficiently important to require patentees and their licensees to "find ways around Brulotte" using other means.  These include deferred payments on royalties earned during the patent term (Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U. S. 100, 136 (1969)) or extending royalties until the last-to-expire of a patent portfolio.  Also permitted would be licensing non-patent rights — such as "know-how" or trade secrets (no matter how closely tied to the patent).  "Finally and most broadly, Brulotte poses no bar to business arrangements other than royalties — all kinds of joint ventures, for example — that enable parties to share the risks and rewards of commercializing an invention" according to the opinion.

    The majority rejected Kimble's argument that these situations be subjected to a "case-by-case," "rule of reason" approach.  This is where the Court most directly resorts to stare decisis principles, stating that "[o]verruling precedent is never a small matter."  The benefits of not doing so include that "it promotes the evenhanded, predictable, and consistent development of legal principles, fosters reliance on judicial decisions, and contributes to the actual and perceived integrity of the judicial process," citing Payne v. Tennessee, 501 U. S. 808, 827–828 (1991).  But in doing so the Court adopts Justice Brandeis' view that "it is usually 'more important that the applicable rule of law be settled than that it be settled right.'"  Burnet v. Coronado Oil & Gas Co., 285 U. S. 393, 406 (1932) (which besides being contrary to the Court's role in actually trying to interpret the laws to effectuate congressional intent, it also must be noted that Justice Brandeis' statement was made in a dissenting opinion and thus not the basis for the Burnet decision.)

    And in a statement that will negatively resonate with those hoping that the Court recognize the error of its thinking regarding subject matter eligibility, the opinion states that "[a]ccordingly, an argument that we got something wrong — even a good argument to that effect — cannot by itself justify scrapping settled precedent."  Rather, the majority believe that "[t]o reverse course, we require as well what we have termed a 'special justification' — over and above the belief 'that the precedent was wrongly decided,'" citing Halliburton Co. v. Erica P. John Fund, Inc., 573 U. S. ___, ___ (2014) (slip op., at 4).

    The majority opinion also states that stare decisis is more important when the Court interprets a statute because the party can "take their objections across the street" and have Congress change the law, citing Patterson v. McLean Credit Union, 491 U. S. 164, 172–173 (1989).  In this case, the majority perceives that Congress has declined this opportunity repeatedly ("long congressional acquiescence"), citing the implementing statutes for the GATT/TRIPS agreements as well as specific bills introduced (but never enacted) aimed at changing the law to abrogate the Brullotte rule.

    Other reasons contained in the majority opinion for refusing to overrule Brulotte include the special characteristics of cases at the nexus between property law and contract law, where the majority believe stare decisis principles to be "at their acme" because such precedents are used by parties when "ordering their affairs."  This reasoning harkens back to the sentiment that the Court should not upset "settled expectations: "[s]o long as we see a reasonable possibility that parties have structured their business transactions in light of Brulotte, we have one more reason to let it stand" (reasoning woefully absent when the Court rendered its Myriad decision).  In addition, the majority believes that Brulotte remains consistent with other precedent supporting "bright line" patent term expiry and that the rule (according to the majority) remains "workable" in practice, particularly when compared with antitrust law.

    The Court majority acknowledges the scholarly consensus that post-expiration royalties can have pro-competitive effects.  But in their view this a patent case, not an antirust case (where the Court has been more flexible due to the dynamic nature of antitrust law), and the public interest trumps: "[s]o in deciding whether post-expiration royalties comport with patent law, Brulotte did not undertake to assess that practice's likely competitive effects.  Instead, it applied a categorical principle that all patents, and all benefits from them, must end when their terms expire."  (This categorical approach is consistent with the Court's views regarding subject matter eligibility.)  And, "[s]o if Kimble thinks patent law's insistence on unrestricted access to formerly patented inventions leaves too little room for pro-competitive post-expiration royalties, then Congress, not this Court, is his proper audience."

    Appeals to innovation, the "wellspring of patent policy," and the rule's harm to innovation provide no help:  "[n]either Kimble nor his amici have offered any empirical evidence connecting Brulotte to decreased innovation; they essentially ask us to take their word for the problem.  And the United States, which acts as both a licensor and a licensee of patented inventions while also implementing patent policy, vigorously disputes that Brulotte has caused any 'significant real-world economic harm,'" citing the government's amicus brief.

    Justice Alito disagreed, characterizing Brulotte as " a clear case of judicial overreach" and saying that in his view the rule was based not on patent law but on antitrust principles that have been "debunked."  Regarding the rationale for the majority opinion, Justice Alito writes that "[o]ur traditional approach to stare decisis does not re­quire us to retain Brulotte's per se rule.  Brulotte's holding had no basis in the law.  Its reasoning has been thoroughly disproved.  It poses economic barriers that stifle innova­tion.  And it unsettles contractual expectations."

    There is one aspect of this opinion that rankles:  the majority's inability not to reference its recent subject matter eligibility decisions as if they were not only properly decided but that they are a proper exercise of the Court's gatekeeping role.  While either of these propositions may be correct (although the latter is likelier than the former), this self-satisfying (and self-satisfied) dicta was not only unnecessary:  it is guaranteed to percolate into the district courts and the Federal Circuit (which can no longer be trusted to speak truth to power when it comes to patent law as it should be) and the PTO, becoming another justification for the legitimate scope of patent rights to be constricted to the point that patents no longer are able to promote progress.  These views threaten not only progress but American competitiveness, raising the question:  when your global advantage is the ingenuity of your population why would anyone think restricting the ability to protect innovation from predation by copiers (foreign and domestic) is a good idea?

    Kimble v. Marvel Entertainment, LLC (2015)
    Opinion of the Court by Justice Kagan, joined by Justices Scalia, Kennedy, Ginsburg, Breyer, and Sotomayor; dissenting opinion by Justice Alito, joined by Chief Justice Roberts and Justice Thomas